Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) marched up 16.97% compared to a 52-week low price of $0.69. The shares were last seen trading -5.35% lower, taking the closing price at $0.8 on 5/23/2019. At a recent session, the prices were hovering between $0.8248 and $0.881. This company shares are 100% off its target price of $1.6 and the current market capitalization stands at $27.54M. The recent change has given its price a -35.8% deficit over SMA 50 and -88.08% deficit over its 52-week high. The stock witnessed -0.86% declines, -57.29% declines and -82.12% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CNAT’s volatility during a week at 7.29% and during a month it has been found around 9.02%.

Conatus Pharmaceuticals Inc. (CNAT) Top Holders

Institutional investors currently hold around $7 million or 26% in CNAT stock. Look at its top three institutional owners: Mpm Asset Management Llc owns $2.09 million in Conatus Pharmaceuticals Inc., which represents roughly 7.59% of the company’s market cap and approximately 29.86% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 1,638,895 shares of the stock are valued at $1.39 million. The third largest holder is Blackrock Inc., which currently holds $1.33 million worth of this stock and that ownership represents nearly 4.81% of its market capitalization.

Conatus Pharmaceuticals Inc. 13F Filings

At the end of March reporting period, 20 institutional holders increased their position in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) by some 1,752,265 shares, 24 decreased positions by 1,577,967 and 13 held positions by 5,138,003. That puts total institutional holdings at 8,468,235 shares, according to SEC filings. The stock grabbed 4 new institutional investments totaling 93,753 shares while 13 institutional investors sold out their entire positions totaling 1,118,240 shares.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Insider Trades

Multiple company employees have indulged in significant insider trading. Conatus Pharmaceuticals Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director KISNER DANIEL L has acquired 4,000 shares of Conatus Pharmaceuticals Inc. (CNAT) in the trading session dated Apr. 08, 2015. These shares are worth $23,000 and were traded at $5.75 each. The SEC filing shows that Malik Shahzad performed a sale of 535 shares. The Director, 10% Owner disposed these shares by way of transaction on Jul. 30, 2013. The company’s shares were given away at $11 per share worth to an income of some $5,885 to the account of Malik Shahzad.

Director, 10% Owner, KLINGENSTEIN PAUL H, sold 566 common shares of Conatus Pharmaceuticals Inc. (CNAT) in the open market. In a transaction dated Jul. 30, 2013, the shares were put up for sale at an average price of $11, raking in a sum of $6,226. After this sale, 2,279,363 common shares of CNAT are directly owned by the insider, with total stake valued at $1,823,490.

In the transaction dated Jul. 30, 2013, a great number of shares acquired came courtesy the President, CEO & Director; Mento Steven J added a total of 13,800 shares at an average price of $11, amounting to approximately $151,800. The insider now directly owns 385,669 shares worth $308,535.

Conatus Pharmaceuticals Inc. (CNAT) Analyst Guide

Several analysts have released their opinion on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), with 0 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 3 average brokerage recommendation [T1].